On the other side of the world.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Someone on RB posted that there could be a rider on a defense expenditure in congress that would fund NNVC since micelles have a bioweapons application. Anyone? Could this be true? Does this guy know something?
I never fault anyone for making a profit. After all, that is why we are here and the market benefits from capital infusion whether it is from day trading or life-time investment. But I always hate to see manipulation to drive a price down at the expense of company value, when that devaluation is undeserved and the manipulation is built on lies and rumors. I find it even more loathsome when it is at the expense of the development of critically needed products.
It already bounced off of 1.50 support and went right back up to 1.85 before slipping again. Some short covering, clearly, but it should come back down to retest support. No bounce then weak support at 1.17 and then solid at 1.05. I don't think it will happen. It takes too little buying to send the PPS back up. Big volume to drop, but little volume to significantly rise. Too, many buyers waiting to find the bottom. I'm one of them, and I'm already in the green from buying at 1.60. Day tradrs will keep it from revovering too quickly. Already see profit taking on buys at 1.55. IMO
Agree. RSI dipped below 30. I would expect opening lower tomorrow followed by a rise back to 1.50-1.55. MMs should peg the last buy above the LOD, maybe even 1.60 to exagerate tomorrow's dip. They did that yesterday when the last buy was posted as 100 shares at 1.80, .10 above the previous sale.
Anyone else here feel slimed?
Wrong Mypointz. Next support is where it's at now. The support after that is the 1.05 level set by the 200 MA.
Sorry. I meant to say that talk about PIPE funding is only fear mongering. No way they would go to the last resort for a corporation that has already run through all its capital and financing sources.
I think that is only fear mongering. There are too many other sources of money for this type of venture. As another poster pointed out, there are too many community grants available for exactly what NNVC is doing.
Sorry, that was an after thought for the poster that did mention HOGC. I will think him/her later personally by alias after I see green. LOL
I look to add more NNVC tomorrow, though honestly I hope that I can't. Took profit from AURC today (5 banger) and using some of that money. I now have shares free and clear in both stocks. Thanks for HOGC, I will look into that also. --Doc
NanoViricides, Inc. Retires 833,600 Shares
Wednesday April 19, 1:10 am ET
Company Finalizes Agreement Regarding Return of Unauthorized Stock and Cancellation of Options
NEW HAVEN, Conn.--(BUSINESS WIRE)--April 19, 2006--NanoViricides, Inc. (NNVC.PK), a biopharmaceutical company specializing in unique antiviral treatments that utilize its patented nanomicelle, today announced several first-quarter updates.
ADVERTISEMENT
CEO Eugene Seymour, MD MPH, announced today that he has signed an agreement with the owners of the original shell company regarding their unauthorized issuance of stock during the transfer process. The original shell owners have agreed to return to the Company their unauthorized 833,600 shares for immediate cancellation. In addition, they agreed to cancellation of 700,000 of their options.
"The fact that the dispute is finally settled," stated Dr. Seymour, "means that we can now ready the company for its move to another exchange."
The agreement enables NanoViricides, Inc. to proceed with the previously planned financial audit and subsequent submission to the SEC. Once NanoViricides, Inc. becomes a reporting company it can then apply for a move to the Bulletin Board (OTCBB) exchange. The Company will then be eligible to apply to the NASDAQ when NASDAQ's financial and stock price requirements have been met.
About NanoViricides - http://www.nanoviricides.com
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. A nanoviricide(TM) is a specially designed, flexible, nanomaterial that contains an encapsulated active pharmaceutical ingredient and targets it to a specific type of virus, like a guided missile. NanoViricides, Inc., drugs are designed to block and dismantle the virus particles before they can infect a cell, thereby controlling viremia. This is a completely novel approach that is proving to be superior to existing approaches.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Forward-looking statements involve risks and uncertainties. Actual events could differ materially and substantially from those projected herein and depend on a number of factors including the success of the Company's research and development strategy, the availability of adequate financing, the successful and timely completion of clinical studies and the uncertainties related to the regulatory process.
50,000 sq. ft = 1.15 acres, or
50,000 sq.ft. = .47 hectare
According to one RB poster today, the production line for a single micelle product can be as small as an average bedroom. Assuming the average bedroom is 12X15 ft. = 180 sq.ft so 10 production lines can fit in 18,000 sq.ft or a little more than 1/3 of the total space. This leaves 32,000 sq. ft for storage, labs and offices.
Another way to look at this is by volume. a 50,000 sq. ft. facility with 20 foot rafters has 23 acre feet of interior space.
Office and storage would only require 10 foot ceilings and then those ceilings would seem spacious and airie. So, if the facility has 20 ft rafters, a mezzanine can be constructed at one end for offices above and storage below. This could easily yeild another 10,000 sq. ft., or a net floor space of 60,000 sq. ft. or roughly 2/3 the space of an average Walmart.
Quick answer, 50,000 sq. ft. is roughly half a Walmart, though some are as small as 70,000 and the largest above 180,000, or 1.67 hectare.
Migration patterns. Of course Bird FLu will be here soon. NNVC to the rescue in the nick of time.
OT: Westeffer, thanks for AURC. I was patient enough to get in at an average price of .07. Moving up hard on no news, except maybe the price of gold and silver. NNVC and AURC are my best performers for the year, so far. --Doc
The quivalent of 50 times the dose means that they use a body mass formula that gives a dosage proportional to what would be given a human. A dosage 50 times the therapeutic dosage for humans would leave a cage full of mice bloated like white, furry balloons with legs. LOL
In all my DD, and I have done a lot, I have not come across one bit of evidence that this is even close to being a scam. The one flag that does continually go up is that NNVC is incorporated in the State of Nevada. Under Nevada rules, a BOD can define shares in pretty much any way they see fit. They can even shield shares from dilution. THat is why when dealing with Nevada corporations one must look at all beneficial owners as well as shares distribution. NNVC has clear checks and balances. No single person can do anything without the consent of at least one other beneficial owner. Also, every single owner has a long reputation for inetgrety and honesty. Sorry, but no scam here.
Testing to be completed in next 12 weeks means that the report would then follow. Evaluation of data and the report might take another 2 to 3 weeks. Sooner than that should be seen as a bonus. I think the PR announcing the results will come after April 15. So, I would look for it on or around April 17th. Although, this week would be great!! IMHO
The only question I have is whether or not each subsequent change in the targeting protein will mean a large enough change that the FDA will require safety testing and approval. One assumes that a pass on FluCide means a pass on AviFluCide and vice versa, but does that also apply to different virus strains? Would HiviCide require simple efficacy studies or would they require rigorous repeat testing of Phases I, II and III? Once FDA approval is met for the underlying, or base, micelle, shouldn't the timeline for each application (HIV, cancer, hepetitus, rabies, etc) be greatly shortened? Expansion of product line and market will be greatly dependent upon how the FDA interprets and applies its current rules regarding polymeric micelle technology.
A vaccine uses an inert or diminished form of the target virus. Because a vaccine is dependent upon a healthy immune system to work, the inert virus must still activate the immune system to react to the invasion as though it were a real problem. Therefore, vaccines carry with them enough harm that the body does react. The reaction can vary from sorness to actual flu symptoms. The symptoms can last several days. Moreover, vaccines have been known to create a number of potentially dangerous side effects ranging from toxic shock, to alergic reactions and even severe reperatory collapse. With a vaccine, there is always the smallest potential for a deadly reaction.
More importantly, a vaccine is only effective if the subject has a healthy enough immune system. If the immune system has collapsed or or is weak, a vaccine will not work. In that case, antibiotics and other theropies must be administered.
Finally, vaccines must be given before the onset of the most critical symptoms. Unlike the movies where the last minute development of a vaccine creates amazing turn arounds in nearly dead patients, a vaccine administered too late in the viral infection cycle will not work. In fact, a vaccine must be given prior to the arrival of a pandemic to be most effective. In many cases a vaccine can be completely ineffective if the immune system has not had enough time to react.
They can't say that the mice all lived because they were killed for autopsy. How do you think the toxicology exam on vital organs was performed. "The survival time of treated mice was increased significantly" most probably means survival until they were euthanized. The life-cycle of the subject was significantly shortened due to the immediacy for lab results. That's a nice way of saying mice were kiled so that other mice (and humans) could live.
If the final report for H2N1 efficacy says that all the mice lived when nearly all should have died, and it further states that the micelles can be easily tweaked for any and all viruses, the a market cap of $1 billion pre-market development will be nothing. I can easily see a $10 billion cap considereing all the applications including HIV, coughs, colds, cat scratch disease, chicken pox, various viral hepetituses (A,B,C,etc.), viral encephalitis, 5 types of dengue, filovirus, viral herpes, viral warts, HTLV imuno-virals, human papillomavirus, infant cytomagelic virus, measles, mumps, orchitis, mononeucleosis, viral pneumonia, rabis, rubella, viral myelitis, west nile fever and yellow fever, and all other mosquito-born flaviviruses.
Can anyone estimate the potential market over the next 15 years?
Anyone want to go out on a limb and predict this week? I say consolidation at $2.80-2.90 until the next PR. I sure hope I'm wrong and the sp keeps on a-goin'!!
Reading between the lines for the last 2 PRs, I'd say that there is less than a 10% chance of failure. The real question should be to what degree will they succeed in Vietnam.
All of this assumes, of course, that the NNVC team is not, as shreiked by Matty and Justice on RB, a big scam of lies and misleading PRs. The obvious assumption here must be that those 2 are paid idiots spouting venom for what ever purposes of their respective string pulling higher authorities.
So, my gut feeling is that when the PR reported that the results were far better than they had expected, I took that to mean that the mice had a 100% survival rate under clinical conditions. I also took it mean that there was no need, in the case of H2N1, for an API, since I seem to recall that they were testing micelle bodning to prevent viral entry and infection of new cells. I believe that they were not testing using an API.
Of course, this is all just IMO since virology and chemical engineering are not my areas of expertise.
As for my self and IMHO, I see a quick progression from current price to a "psychological resistance" in two steps. First resistance should be 4.50 - 5.00. and then 8.00 - 10.00. After each run, there should be a 50% to 65% retracement of the run before the next leg up.
I've increased my shares by 25% with that strategy and taken some profits at the same time. It's important to watch the ROC closely during the run to get a sense of timing.
I would have liked to have had the information on the company and its leadership back when I first heard of NNVC, which was under .10. I didn't get in until over .20, and then it wasn't nearly enough since I didn't complete my DD until it was already at .80 range. Oh, well. At least I hold enough that if this hits I will buy that nice Kaua`i cliff property I've always wanted.
RB, for some reason, won't let me post this:
Couch: The stats from yesterday were taken from
http://faculty.fuqua.duke.edu/~willm/Classes/Pharma2005/Materials/07_Claritin/Case&Readings/c07s...
Yes, I know that Duke University faculty are usually not very reliable, as Matty wild point out, nonetheless, I think that their projected global sales and market sector stats for 2007 are close enough for our purposes here.
Yes, these stats are OTC meds, but they do directly correlate with market potential for Flucide. The fact that more than 36 billion US is spent worldwide on Flu related OTC products indicates the real market potential for elective spending when it comes to health and flu virus infections.
You are correct in pointing out that 90 million in the US come down with flu anually, however, we are talking about the entire developed world, which includes Europe and parts of Asia. The US makes up only 1/5th of the developed world. And, China now has an affluent middle-class numbering over 100 million. Therefore, only counting Europe, North America, and parts of East Asia, my estimate would be market regions for Flucide would yeild 3 to 5 times the 90 million you indicate (probably higher) cases of treatable flu per year. The question then is nothing more than will people spend $50-$100 for a flu cure at the beginning of flu symptoms in order to maintain productivity and health.
Current treatment for flu still allows the virus to ravage the reperatory system. Healing often takes more than 30 days before the system is back at 100%. In the case of severe influenzas, symptoms such as coughing, wheezing and expectoration can last 2 months or more. Thus the only question is would people then be likely to spend $100 to quickly and efficiently stop the ravages of flu at the very onset of symptoms?
Couch: When you crunch the numbers, are you using North American, European, Western or world markets?
Over-the-counter pharmaceutical sales globally are projected to be US$108 billion in 2007. 36% of those sales are cough, cold, analgesics, and headache medications --that is, medications associated with flu viruses. That is not the total market, but it gives an idea of the potential sales for a Flucide. People will choose to be cured as opposed to relief medicated. Global sales, even without a pandemic could still capture 1/4 of the available market that currently goes toward OTC flu related medicines.
So, $9 billion as a potential market for Flucides? How would that translate into share value?
Assuming a P/E of a modest 20/1 for a pharma with earnings of only 10% net of gross and we have $180 a share for Flucide. Perhaps $200 a share is too low, however, I'm still sticking with the Nanoviricide 5 year Timeline. Anything sooner is simply a bonus.
The mice didn't die of H2N1, and H5N1 is still being tested, AND there are hints of rabies efficacy in that last PR. Real news due in 3 weeks and that will send NNVC into LSO (Low Solar Orbit). I'm going out on a limb here and predict NNVC will hit, or surpass, $7.50 within 5 weeks. I now have absolute confidence in Dr. Diwan's theories for targeting micelles.
Let me ask:
1) How much would a safe, painless and effective cure for rabies be worth? Your child or pet is bitten and treatment is currently a series of painful shots and the pet must be quarentined until incubation period has expired. What if such an event now meant nothing more than getting Anti-rabies micelles into the blood stream. Sales would be worldwide. What is the free market value?
2) Effective influenza treatment. Flu epidemic in your child's school? No problem. At the first symptoms of influenza infection, simply inhale a few doses and the virus is destroyed. What would that be worth in the multi-billion dollar cold and cough market?
3) HIV. Need I say more?
4) Cancer targeting. Both viral causes of cancer and cancer cells themselves. What would that be worth since current treatment runs into the 10s of thousands of dollars per individual case?
Perhaps $200 a share is to low for a 5 year target.
OT: BLDH See post #340. Am I good on rare occassions or what. LOL
I got in at .22 and added more at .84. Sold some at 2.50, but bought back in at 1.55. My next trigger, and only a small fraction of my holdings, is between 4.00 and 5.00. I may change that if the roc turns high at the brakout above 2.80 top. If big, big news is immenent, within next 4 weeks, this will triple from that current all-time high. But, I think that even that price will eventually prove to be just the beginning.
"The singularity is near." And, NNVC could well be a part of that revolutionary singularity.
I wish you luck on your forcaste, double10x, and hope that you don't go from Nostradamus 10X to Nostradumbass 1/10X.
Of course, you went to the website. Now why didn't I think of that?
Yep, something in the pipe for NNVC. The only question is what will it be. Up 35% on no news. I hope the news, whatever it is, warrants all the buzz.
OT: BLDH This section of the January 17 filing shows 11,550,015 shares issued and outstanding with 54.66% voting on the amendment.
http://www.sec.gov/Archives/edgar/data/1105309/000114420406001590/v033335_ex3-2x2x1.jpg
And this section of the filing shows a reduction in authorized shares from 50,000,000 to 25,000,000 as a condition of the resolution to change the name from Safe Idea to Bloodhound.
http://www.sec.gov/Archives/edgar/data/1105309/000114420406001590/v033335_ex3-1x1x1.jpg
Then Campbell was issued 500,000. The other shares were already distributed from Sept. 30, 2004 and would be included in the o/s that was r/s.
http://www.sec.gov/Archives/edgar/data/1105309/000114420406003735/xslF345X02/v034364_ex.xml
So, half of 11,550,015 is 5,755,008 plus 500,000 issued to David Campbell gives a total of 6,255,008 in the o/s. Where did you see the other roughly 1,000,000 shares?
PS. This gets more interesting by the minute.
OT: BLDH
I would be careful with this if are planning to buy in at this point. It is a Nevada registered company with unproven technology claims. Here is the problem: Nevada allows the BOD and majority shareholders to structure and issue shares in pretty much any way they see fit. As a microcap, under $25 million market cap, it comes under seperate SEC regulations, oversight and filing requirements. Smallcap requirements kick in after $25 million cap.
According to the last Q report
Class Outstanding as of September 30, 2005
------ ------------------------------------
Common Stock, $0.0001 11,550,015
the current cap should be in the $15 million range. The upper sp boundary for microcap is about $2.10. Since reporting and share release is so lax, I would think that dumping is possible beginning at the current sp, and definitely by $2.
Inductively, a small position at current prices and hold off adding to your position until it breaks the 2.15 sp. That price is the test price for BLDH for legitimizing corporate intentions as a Nevada based microcap. IMO
In my opinion:
1) Vietnam because that is where the first cases were confirmed and they have already isolated and cultured quantities of the virus. The deal was in the works before cases were confirmed outside that area, with the exception of China.
(2) Not China for two reasons: (i) China wants to do the research themselves and is reluctant to part with the virus. (ii) China makes deals and then steals technology. They would insist on the tests being done on their own soil if they supplied the virus. (iii) Undoubtedly China would use the deadly nature of the virus as rationale for disallowing testing of their virus elsewhere. Naturally, they would refuse to allow such a contagion to leave the country. (iv) Research would be completed under their inspection, in their labs, and with their technicians [Read: steal the technology by reverse-engineering the test samples].
(3) Vietnam became desperate enough to agree to use Tamiflu. They then found that even when they used the correct dosage protocol, they still had patients die. [Do nothing and Bird Flu damage takes 2 months to heal. Take Tamiflu and the symptoms only last 60 days.)
(4) Vietnam is a non-aligned country, which means that they are currently relatively free of outside political pressure and influence. The governments of the USA, France, Great Britain, China, Germany and Russia all have limited influence in Vietnam. Therefore they are free to choose "non-conventional" approaches as opposed to more conventional WHO approved approaches [Read: vaccinate, quarantine and sterilize].
Reminds me of the fable about the peasant who rescues the king's daughter from drowning. The king offers the peasant anything he wants: jewels, gold, land. The peasant instead asks for a chess board and some corn. He says to put a kernel on the first square and tomorrow to put 2 kernels on the second square. Then each day double the number intil the last square on the last day. The king agrees. On the 4th day the king owes the peasant 8 kernels. But by the 30th day, the king owes the peasant half a billion kernels of corn for that day alone, and the series is still less that half finished. By the 40th day the king cannot possibly produce the amount of corn needed. The peasant instead tells the king, "In that case I will settle for your crown, scepter, throne and kingdom."
The king thinks for a moment and then orders the peasant be hung. Such is the power of doubling. LOL
I think that selling half at the double shows good discipline. I can't count the number of times I have held a "sure thing" beyond a triple, though I don't do that all the time. Much. LOL Then again, how many times have I taken my profits and decided to double down on the pull-back. Ouch. For this one, I didn't pick up enough to take profits yet, even though I'm holding since .75 range. Really wish I had bought more. My first trigger is at 4.50. Selling only enough to pay for the ride. GLTA from me too.
dmaurici has been cleaning basher clocks over on RB. Hard to tell if s/he is a pumper, paid tout or a real doc with real interest in the technology. Sure knows his/her stuff, though.
That was a very interesting close. dmaurici and Ken on RB seem to think that there is something coming tomorrow or Monday. I agree. Looks to me like MMs were scrambling for shares in the last 1/2 hour. Also, both the bid and ask rose and formed a 20 cent spread. Seems to mean insiders pulled their sells and buyers are still outside the information loop. PR coming? It is due. Might be the follow-up from the previous PR.
RB back up and Matty still posting. Seems to be talking to himself. LOL
I like it. More future reveue.